Wordt geladen...
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
BACKGROUND: Psoriasis is a chronic inflammatory disease that predominantly affects the skin. Adalimumab (HUMIRA(®), AbbVie, Maidenhead, UK), etanercept (Enbrel(®), Pfizer, New York, NY, USA) and ustekinumab (STELARA(®), Janssen Biotech, Inc., Titusville, NJ, USA) are the three biological treatments...
Bewaard in:
| Gepubliceerd in: | Health Technol Assess |
|---|---|
| Hoofdauteurs: | , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
NIHR Journals Library
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5694897/ https://ncbi.nlm.nih.gov/pubmed/29105621 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta21640 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|